Melanoma Clinical Trials in Nashville

Showing 201-220 of 286 trials

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

NCT02359851

This phase II trial studies how well pembrolizumab works in treating patients with uveal melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells.

Stage IIIA Uveal MelanomaStage IIIB Uveal MelanomaStage IIIC Uveal Melanoma+1 more

Vanderbilt-Ingram Cancer Center5 participantsStarted May 2015

Chicago, Illinois, United States • Nashville, Tennessee, United States

COMPLETEDPhase 2< 1 mile

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

NCT02039947

This is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma that has metastasized to the brain. This study will evaluate the safety and efficacy of 4 cohorts. Cohorts will consist of; V600 E, D, K, R mutations, metastases to the brain, symptomatic and asymptomatic, with or without prior local (brain) therapy, with or without prior local (brain) therapy, and range of ECOG scores from 0-2.

Melanoma and Brain Metastases

Novartis Pharmaceuticals127 participantsStarted Feb 2014

Birmingham, Alabama, United States • San Francisco, California, United States • Aurora, Colorado, United States +44 more locations

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Melanoma Trials in Other Cities

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Safety Study of PLX4032 in Patients With Solid Tumors

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

A Study of Vemurafenib in Participants With Metastatic Melanoma

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Other Conditions in Nashville